Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 09:48AM ET
34.53
Dollar change
+0.53
Percentage change
1.56
%
IndexRUT P/E- EPS (ttm)-2.77 Insider Own5.91% Shs Outstand123.90M Perf Week14.34%
Market Cap4.28B Forward P/E- EPS next Y-2.47 Insider Trans-3.96% Shs Float116.58M Perf Month4.60%
Income-296.81M PEG- EPS next Q-0.48 Inst Own62.56% Short Float7.52% Perf Quarter19.40%
Sales181.74M P/S23.54 EPS this Y-40.09% Inst Trans-1.58% Short Ratio5.04 Perf Half Y27.18%
Book/sh1.49 P/B23.14 EPS next Y8.01% ROA-39.11% Short Interest8.77M Perf Year6.90%
Cash/sh1.78 P/C19.42 EPS next 5Y7.33% ROE-110.45% 52W Range20.67 - 42.48 Perf YTD12.84%
Dividend Est.- P/FCF- EPS past 5Y-24.19% ROI-54.04% 52W High-18.71% Beta0.74
Dividend TTM- Quick Ratio3.73 Sales past 5Y205.96% Gross Margin92.26% 52W Low67.05% ATR (14)1.87
Dividend Ex-Date- Current Ratio3.73 EPS Y/Y TTM-89.69% Oper. Margin-164.75% RSI (14)61.34 Volatility8.06% 5.73%
Employees525 Debt/Eq2.45 Sales Y/Y TTM-34.71% Profit Margin-163.32% Recom1.57 Target Price55.15
Option/ShortYes / Yes LT Debt/Eq2.42 EPS Q/Q-217.40% Payout- Rel Volume1.06 Prev Close34.00
Sales Surprise-89.52% EPS Surprise-54.81% Sales Q/Q-94.32% EarningsFeb 06 AMC Avg Volume1.74M Price34.53
SMA2010.81% SMA506.96% SMA20012.52% Trades Volume173,525 Change1.56%
Date Action Analyst Rating Change Price Target Change
Dec-04-23Initiated BofA Securities Buy $29
Sep-19-23Initiated Citigroup Neutral $33
Jul-21-23Initiated TD Cowen Outperform
May-12-23Downgrade SVB Securities Outperform → Market Perform $40
Apr-26-23Initiated SMBC Nikko Outperform $80
Apr-12-23Upgrade SVB Securities Market Perform → Outperform $21 → $35
Mar-21-23Initiated Bernstein Mkt Perform $27
Sep-09-22Initiated Morgan Stanley Equal-Weight $41
May-11-22Upgrade Robert W. Baird Neutral → Outperform $71 → $60
Jan-19-22Resumed Goldman Buy $90 → $85
Feb-07-24 10:42AM
10:02AM
Feb-06-24 04:32PM
04:32PM
04:01PM
04:01PM Loading…
Jan-22-24 04:01PM
Jan-18-24 05:37AM
Jan-09-24 03:02AM
Jan-06-24 01:01PM
Jan-05-24 05:00PM
11:02AM
Jan-03-24 07:00AM
Dec-29-23 04:01PM
Dec-24-23 09:01AM
Dec-21-23 07:30AM
07:30AM Loading…
Dec-20-23 07:30AM
Dec-01-23 09:32AM
Nov-30-23 12:22PM
Nov-29-23 04:51PM
04:01PM
Nov-28-23 07:30AM
Nov-22-23 09:46PM
Nov-21-23 04:01PM
Nov-16-23 07:30AM
Nov-13-23 09:30AM
Nov-06-23 07:30AM
Nov-02-23 07:30AM
Oct-31-23 08:30AM
07:46AM
Oct-28-23 05:02AM
04:01PM Loading…
Oct-03-23 04:01PM
Sep-27-23 04:30PM
Sep-21-23 05:01AM
Sep-11-23 07:30AM
Sep-09-23 03:59PM
Sep-07-23 07:34PM
Sep-01-23 07:30AM
Aug-13-23 08:32AM
Aug-10-23 08:10AM
Aug-08-23 09:42AM
09:13AM
06:20AM
Aug-07-23 04:16PM
04:01PM
Jul-24-23 04:00PM
Jul-17-23 07:30AM
Jul-06-23 04:30PM
Jun-30-23 06:52AM
Jun-27-23 07:30AM
Jun-24-23 08:15AM
Jun-21-23 08:00PM
Jun-14-23 06:34PM
Jun-06-23 07:30AM
Jun-01-23 04:07PM
07:30AM
07:07AM
May-23-23 07:30AM
May-16-23 07:30AM
May-15-23 04:00PM
May-11-23 09:27AM
May-10-23 06:25AM
May-04-23 06:24AM
May-02-23 04:17PM
04:01PM
Apr-26-23 08:00PM
07:06AM
Apr-25-23 01:19PM
11:20AM
07:30AM
Apr-18-23 07:30AM
Apr-17-23 08:17AM
Apr-16-23 05:21AM
Apr-12-23 07:30AM
Apr-04-23 04:30PM
07:30AM
Apr-03-23 07:30AM
Mar-31-23 04:30PM
Mar-20-23 07:30AM
Mar-06-23 05:28AM
Mar-03-23 07:30AM
Feb-28-23 07:30AM
Feb-26-23 08:04AM
Feb-15-23 11:29AM
07:30AM
Feb-08-23 02:13PM
05:34AM
Feb-06-23 04:00PM
Feb-03-23 12:50PM
Feb-02-23 07:30AM
Jan-25-23 07:30AM
Jan-24-23 08:22AM
Jan-10-23 10:15AM
Jan-09-23 10:12AM
Dec-21-22 04:00PM
07:30AM
Dec-20-22 07:30AM
Dec-15-22 04:30PM
11:19AM
Dec-08-22 08:00AM
Nov-30-22 05:23AM
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anzalone Christopher RichardChief Executive OfficerJan 31Option Exercise14.5457,499836,0353,772,547Feb 02 05:25 PM
Anzalone Christopher RichardChief Executive OfficerJan 31Sale32.3557,4991,860,0193,715,048Feb 02 05:25 PM
Hamilton James CChief Discovery/Trans MedicineJan 12Sale36.897,940292,904210,851Jan 17 06:32 PM
Vakiener VictoriaDirectorJan 11Sale38.104,720179,81332,001Jan 16 06:06 PM
Waddill William D.DirectorJan 11Sale38.073,934149,75947,870Jan 16 06:06 PM
Ferrari MauroDirectorJan 11Sale38.063,147119,78760,778Jan 16 06:06 PM
GIVEN DOUGLAS BDirectorJan 11Sale38.062,911110,788129,711Jan 16 06:06 PM
Hamilton James CChief Discovery/Trans MedicineJan 05Sale35.1832,1431,130,748218,791Jan 05 08:02 PM
O'Brien PatrickCOO and General CounselJan 05Sale35.2722,841805,716464,385Jan 05 07:58 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 05Sale35.2716,104567,910440,600Jan 08 05:16 PM
San Martin JavierChief Medical OfficerJan 05Sale35.268,303292,804198,497Jan 08 05:16 PM
Oliver TracieChief Commercial OfficerJan 05Sale33.89742,508136,501Jan 08 05:17 PM
O'Brien PatrickCOO and General CounselJan 04Sale32.631,60052,208402,226Jan 05 07:58 PM
O'Brien PatrickCOO and General CounselJan 03Sale32.288,749282,439403,826Jan 05 07:58 PM
Hamilton James CChief Discovery/Trans MedicineJan 03Sale32.196,300202,781175,934Jan 05 08:02 PM
Anzalone Christopher RichardChief Executive OfficerJan 02Sale31.019,952308,6373,715,048Jan 04 05:25 PM
Anzalone Christopher RichardChief Executive OfficerDec 20Sale28.5412,000342,4803,725,000Dec 22 05:04 PM
San Martin JavierChief Medical OfficerNov 20Sale28.8019,700567,315131,800Nov 22 02:31 PM
Anzalone Christopher RichardChief Executive OfficerOct 25Sale24.2124,338589,2233,737,000Oct 27 06:23 PM
Vakiener VictoriaDirectorSep 28Sale26.331,55040,81221,734Oct 02 05:51 PM
Anzalone Christopher RichardChief Executive OfficerSep 18Option Exercise4.7557,755274,3363,819,093Sep 20 06:10 PM
Anzalone Christopher RichardChief Executive OfficerSep 18Sale28.1257,7551,624,2233,761,338Sep 20 06:10 PM
Oliver TracieChief Commercial OfficerJul 03Sale35.318,925315,14261,575Jul 06 06:04 PM
Hamilton James CChief Discovery/Trans MedicineJun 30Sale35.533,000106,590188,484Jul 05 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJun 27Sale36.2015,000543,000381,704Jun 29 06:41 PM
GIVEN DOUGLAS BDirectorMay 05Sale40.906,500265,850117,635May 08 06:29 PM
Anzalone Christopher RichardChief Executive OfficerMay 04Option Exercise2.0150,000100,5003,811,338May 05 07:04 PM
Anzalone Christopher RichardChief Executive OfficerMay 04Sale39.5250,0001,975,7923,761,338May 05 07:04 PM
Anzalone Christopher RichardChief Executive OfficerMay 03Option Exercise2.0154,928110,4053,816,266May 05 07:04 PM
Anzalone Christopher RichardChief Executive OfficerMay 03Sale39.1454,9282,149,8823,761,338May 05 07:04 PM
OLUKOTUN ADEOYE YDirectorMar 03Sale32.6511,350370,5787,867Mar 06 06:04 PM